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EGFR belongs to the HER/ErbB family of tyrosine kinase receptors and its activation in cancer cells has been linked with
increased proliferation, angiogenesis, andmetastasis. Lymphangioleiomyomatosis (LAM) is a rare, low-grade neoplasm that occurs
sporadically or in association with tuberous sclerosis complex (TSC), a genetic, multisystem disorder characterized by hamartomas
in several organs. From chylous of a LAM/TSC patient, we previously isolated smooth muscle-like LAM/TSC cells whose
proliferation depends on EGF andmonoclonal anti-EGFR antibodies reduced proliferation and caused cell death.We demonstrated
that the dependency from EGF was caused by the absence of tuberin. To study the role of EGFR pathway in vivo, we developed a
mouse model by administration of LAM/TSC cells to female nude mice. LAM/TSC cells caused pulmonary airspace enlargement
and, after 30 weeks, nodule formation which express EGFR. Anti-EGFR antibody decreased the number and dimension of lung
nodules likely for the inhibition of Erk and S6 signaling, reversed the pulmonary alterations, and reduced lymphatic and blood
vessels. Moreover, in pulmonary nodules anti-EGFR antibody reduced the positivity to estrogen and progesterone receptors which
enhance survival of LAM cells and Snail expression. These results suggest that the inhibition of EGFR signalling has a potential in
treatment of LAM/TSC lung alterations.
1. Introduction
Epidermal growth factor receptor (EGFR) is a key signaling
pathwaywith a relevant role in several physiologic and patho-
logic processes [1]. The EGFR belongs to the ErbB family
of four closely related cell membrane receptors which are
transmembrane glycoproteins that consist of an extracellular
ligand-binding domain, a transmembrane domain, and an
intracellular domain with tyrosine kinase activity for signal
transduction. EGFR is involved in transductional signal
cascades regulating cellular processes such as proliferation,
survival, adhesion, migration, and differentiation [1]. EGFR
activation initiatesmultiple pathways involving effectors such
as phosphatidylinositol 3-kinase-AKT, mammalian target of
rapamycin (mTOR), Src tyrosine kinase, protein kinase C,
and p27 [1]. The activation of these pathways is related to
several aspects of development and tissue homoeostasis [2].
Moreover, the aberrant expression of EGFR has an important
role in the development and growth of tumor cells.
Lymphangioleiomyomatosis (LAM), a rare lung disease
affecting predominantly women of childbearing age, is char-
acterized by cystic lung destruction, abdominal tumors such
as angiomyolipomas, infiltration of the axial lymphatics in
the thorax, and abdomen, and chylous pleural effusions [3].
LAM lesions generally express estrogen receptor (ER) and
progesterone receptors (PR) suggesting that the development
of the disease is, at least in part, hormone related [4]. The
preeminent histological feature of LAM is the presence of
smooth muscle-like cells in pulmonary and extrapulmonary
lesions [5]. Lung LAM cells may develop as nodular struc-
tures which are histologically benign and have the potential
to metastasize in vivo [6–8]. Several evidences suggest that
LAM cells migrate to the lung from other tissues through
lymphatics or, possibly, the bloodstream [8, 9]. LAM can
be sporadic or associated with tuberous sclerosis complex
(TSC), an autosomal dominant syndrome, characterized by
multisystem manifestations, which can include neurologic
disease and benign tumors in multiple organs such as brain,
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skin, and kidney. Tuberin andhamartin, the products ofTSC2
and TSC1 genes, respectively, form a complex that functions
as an upstream modulator of the mTOR, a regulator of cell
cycle progression, cell growth, and proliferation [10, 11]. Loss
of tuberin results in a constitutively activated mTOR sig-
nalling leading to increased cell growth [8]. In a recent clinical
trial sirolimus, anmTOR inhibitor, stabilized lung function in
LAM patients but the effects were restricted to the treatment
period [12]. In TSC, everolimus, a rapamycin analogue,
reduced renal angiomyolipoma volume that tended to regain
the previous size after therapy suspension [13].
We isolated human smooth muscle-like TSC2-deficient
cells from chylous effusion of a patient affected by LAM asso-
ciatedwithTSCbearing aTSC2mutationswith no expression
of tuberin for an epigenetic modification such as 𝑇𝑆𝐶2−/meth
ASM cells [14, 15]. Though LAM/TSC cells are smooth
muscle-like cells, they showed epidermal growth factor (EGF)
dependency for proliferation and survival, and incubation
with monoclonal anti-EGFR antibodies, directed against the
extracellular ligand-binding domain, causes cell death [15].
We have previously demonstrated that EGF dependency is
related to the lack of tuberin, and TSC2-transfection and
induction of tuberin expression reverse this characteristic
feature [14–17]. Pathways involving mTOR integrate growth
factor signals and are regulated by several growth factors such
as EGF and hepatocytes growth factor [18]. It has also been
demonstrated that EGFR and EGF expression is increased in
𝑇𝑠𝑐1
GFAP CKO mouse cortex, in tubers and subependymal
giant cell astrocytomas (SEGAs) of TSC patients [19].
In this study LAM/TSC cells were endonasally admin-
istered to immunodeficient female athymic nude mice;
the following lung infiltration was accompanied by nodule
formation and enlarged alveolar spaces. Since LAM/TSC
cells are EGF dependent for survival and proliferation, we
evaluated the effect of the blockade of EGFR activation on
lung lesions and nodule. Anti-EGFR antibody reversed the
pulmonary alterations, nodule number and dimension, lym-
phangiogenesis, and angiogenesis caused by LAM/TSC cells.
Moreover, anti-EGFR antibody reduced the expression of
estrogen and progesterone receptors and Snail in pulmonary
lesions. The effects of anti-EGFR antibody were compared
to those of rapamycin, a specific inhibitor of mTOR, with
clinical efficacy in LAMandTSC [12, 13]. Since not all patients
respond to rapamycin and, upon rapamycin withdrawal, lung
function declines and hamartomas regain ability of growth,
we consider quite relevant the investigation of the role of
other pathways which may result in useful additional targets
for curing LAM and TSC. Here we show that the blockade of
EGFR function may have a potential therapeutic value.
2. Materials and Methods
2.1. Antibodies and Major Reagents. Salts were purchased
from Sigma-Aldrich (St. Louis, MO, USA). For cell treat-
ment, monoclonal anti-EGFR antibody, directed against
the extracellular ligand-binding domain (clone 225), was
supplied by Calbiochem (Darmstadt, Germany); for animal
treatment, anti-EGFR antibody was supplied by Merck
(Darmstadt, Germany); for cell and animal treatments,
rapamycin (Rapamune-Sirolimus) was supplied by Wyeth
Europa (UK).
Antibodies against phospho-p44/42 mitogen-activated
protein kinase (MAPK), phospho-S6 ribosomal protein,
Snail, and EGFR were purchased from Cell Signaling Tech-
nology (Danvers, MA). Antibodies against 𝛽-actin and 𝛼-
actin were purchased from Sigma-Aldrich. Antibody against
human leukocyte antigens HLA-A, B, and C, was pur-
chased from Biosciences (Le Pont-De-Claix Cedex, France).
Antibody against lymphatic vessel endothelial hyaluronan
receptor-1 (LYVE-1) was purchased from R&D System (Min-
neapolis,MN).Antibodies against ER andPRwere purchased
from Santa Cruz (Santa Cruz, CA). Secondary antibodies
horseradish peroxidase conjugated were purchased from
Pierce (Rockford, USA) and Alexa Fluor dyes were from
Invitrogen (Camarillo, CA, USA).
2.2. Cell Culture. LAM/TSC cells were isolated, character-
ized, and grown as previously described. Briefly, the cells were
obtained from chylous effusion of a LAM/TSC patient who
had givenwritten informed consent according to theDeclara-
tion of Helsinki. The study was approved by the Institutional
Review Board of Milan’s San Paolo Hospital. LAM/TSC
cells were previously described [15]. The culture medium
contained a 50/50 mixture of DMEM/Ham F12 (Euroclone,
Paignton, UK) supplemented with 200 nM hydrocortisone
(Sigma-Aldrich, St. Louis, MO), 10 ng/mL epidermal growth
factor (EGF, Sigma-Aldrich), 1,6 𝜇Mferrous sulphate (Sigma-
Aldrich), and 15% fetal bovine serum (Euroclone). LAM/TSC
cells were used at 15 to 20 passages. As previously reported,
these cells can be grown as a stabilized cell line and
were checked routinely for morphological, biochemical, and
genetic features. COS7 cells (fibroblast-like cells, ATCC,
Manassas, USA) were maintained in DMEM containing 10%
FBS.
2.3. Animal Experiments and Pharmacological Treatments.
Immunodeficient female nude mice nu/nu Hsd : athymic
were obtained from Harlan Laboratories (Udine, Italy). All
experimental procedures were performed in accordance with
the Italian Guidelines for Laboratory Animals, which con-
forms to the European Committees Directive (86/609/EEC),
and study protocols were previously approved by the Min-
istero della Sanita` (2/2011 Protocol). Mice were housed in
individual plastic cages under controlled conditions (tem-
perature: 22-23∘C with light/dark cycle of 12 h) with food
and water at libitum. LAM/TSC cells were labelled with
PKH26-GL using Red Fluorescent Cell Linker kits (Sigma-
Aldrich). Cells were incubated with PKH26-GL in diluent
C at 37∘C for 4 minutes and the reaction was stopped by
adding an equal volume of FBS. The cell suspension was
centrifuged, washed with DMEM, and resuspended in 25𝜇L
of physiological solution (0.9%NaCl) before administering to
the mice. After light anesthesia by intramuscular injection of
4% chloral hydrate, 2 × 105 LAM/TSC cells were endonasally
administered in 70 nude mice (3 weeks old) using a microtip
and allowing the mice to breathe the drop of physiological
solution containing the cells.Themortality was 13% and 20%,
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respectively, 30 and 60 weeks after cell administration while
no deaths occurred at 15 weeks. 26 weeks after endonasal
cell administration, mice were randomly divided into four
groups: (a) LAM/TSCmice (𝑛 = 15; 2 deaths), (b) LAM/TSC
mice treated with anti-EGFR antibody (𝑛 = 15; 2 deaths),
(c) LAM/TSC mice treated with 4mg/kg rapamycin (𝑛 =
15; 4 deaths), and (d) control mice treated with the vehicle
(𝑛 = 15). Anti-EGFR antibody and rapamycin were admin-
istrated intraperitoneally (i.p.) twice weekly for 4 weeks.
Anti-EGFR antibody was administrated at a starting dose of
400mg/m2 followed by a subsequent dose of 250mg/m2 and
rapamycin was administrated at 4mg/kg. 15, 30, or 60 weeks
after endonasal cell administration, mice were sacrificed by
exsanguination under 4% chloral hydrate anesthesia. Lungs
and lymph nodes were removed as described by Lesma et al.
[20]. All specimenswere fixed in 4%paraformaldehyde at 4∘C
overnight and embedded in paraffin.
2.4. Western Blotting. Cells were lysed in lysis buffer
(1.9mg/mL EDTA, 8.2mg/mL deoxycholic acid, and 3%
SDS), electrophoretically run on a 10% sodium SDS-PAGE,
and transferred to nitrocellulose membranes (Amersham,
Arlington Heights, IL). After being blocked at room temper-
ature for 1 h with 5% dry milk (Merck Millipore, Darmstadt,
Germany), membranes were incubated overnight at 4∘C
with primary antibodies and then for 1 h with appropriate
secondary antibodies. The reaction was revealed using the
Amersham ECL Prime Western Blotting Detection Reagent
(GE Healthcare, UK). Images were acquired on a Kodak
image station 440CF.
2.5. Lung Histology. Five 𝜇m thick sections from lung
paraffin-embedded samples were sectioned, deparaffinized,
and rehydrated in xylene and graded concentrations of
ethanol to distilled water. Sections were stained with hema-
toxylin and eosin for histological analysis. Images of lung
tissue sections were acquired with LEICA DM4000 B micro-
scope.Thedensity of air-exchanging parenchyma,𝐴
𝐴
(ae/lu),
was determined by point counting based on computer-
assisted image analysis. The number of points falling on
air-exchanging parenchyma (peripheral lung parenchyma
excluding airspace) in random lung fields was divided by
the number of points falling on the entire field (tissue
and airspace). Airways, vascular structures, and histological
mechanical artifacts were eliminated from the analysis. Pres-
ence of lung nodules was determined by two independent
observers by counting mice that presented nodules in lung
in hematoxylin and eosin stained sections. The number of
mice showing nodules was expressed as percentage. Blood
vessels were hand-counted by light microscope (10x) in
hematoxylin-eosin sections and expressed as vessels/field.
2.6. Immunohistochemical Analysis. Immunohistochemical
analysis was performed according to the staining procedure
provided by ABC Ultrasensitive Peroxidase Staining kit
(Pierce, Rockford, IL USA) or ABC-AP Vector Laboratories
kit (Vector Laboratories, Burlingame, CA). Sections were
deparaffinized, rehydrated, and heated to 95∘C for 20minutes
in citrate buffer (pH 6.0) for antigen retrieval. After cooling
to room temperature, sections were incubated with 0,3%
H
2
O
2
in methanol for 20 minutes to quench endogenous
peroxidase activity and then incubated in 3% bovine serum
bovine/TBS at room temperature for 2 hours to block non-
specific binding. Slides were incubated overnight at 4∘C in a
moist chamber with primary antibody. Slides were incubated
with appropriate secondary antibody for 2 hours at room
temperature and ABC Ultrasensitive Peroxidase Staining kit
(Pierce) or ABC-AP Vector Laboratories (Burlingame, CA)
were used for signal enhancement. Peroxidases substrate
DAB (3.3-diaminobenzidine) (DAB substrate kit, Pierce) or
Vector RedAlkaline Phosphatase Substrate was used for color
development. Finally, the sections were counterstained with
Mayer’s hematoxylin, dehydrated, and mounted.
2.7. Immunofluorescence Analysis. Sections of lymph nodes
and lungs were blocked with 3% bovine serum/TBS at room
temperature for 2 hours and incubated overnight at 4∘C
in a moist chamber with primary antibodies. Cells were
fixed in 70% methanol and blocked with 4% bovine serum
at room temperature and incubated overnight at 4∘C with
primary antibodies. Staining was revealed with an appropri-
ate secondary antibody Alexa Fluor dyes and nuclei were
stained with 2 𝜇g/mL DAPI (Sigma-Aldrich). Samples were
analyzed using a laser scanning confocal microscope (LEICA
DMIRE2, Wetzlar, Germany).
2.8. Statistical Analysis. The significance of differences
between experimental groups was calculated using Student’s
t-test or one-way ANOVA analysis as appropriate. In all
cases, 𝑃 values less than 0.05 were considered statistically
significant. Analysis was performedwith theGraphPadPrism
5 (version 5, GraphPad software, Inc.).
3. Results
3.1. LAM/TSC Cells Cause Multiple Lesions and Airspace
Enlargement in Nude Mice Lungs. LAM/TSC cells were
isolated from chylothorax of a patient affected by LAM
associated with TSC [15] and endonasally administered to
3-week-old female nu/nu HSD : athymic nude mice, when
the mice have not yet reached the sexual maturation. 15,
30, and 60 weeks after administration, LAM/TSC cells were
detected in mice cervical, mediastinic, and retroperitoneal
lymph nodes by positivity to HLA-A, B, and C antibody and
in lungs by means of PKH-26 fluorescence (Figure 1). This
shows the capability of LAM/TSC cells to disseminate in vivo,
as it was previously demonstrated for TSC2−/− 𝛼-smooth
muscle actin (ASM) cells [20]. LAM/TSC cell accumulation
in lungs caused the formation of multiple lung nodules
30 and 60 weeks after cell inhalation with a quantitative
estimate of about 77% and 87%, respectively (Figure 1(b)
and high magnification view of LAM nodules Figure 1(c)).
Lung lesions were not found in the lungs of nude mice at
earlier time, 15 weeks after cell administration. 𝛼-Actin was
expressed in cells of lung lesions as it occurs in human LAM
nodules and was mainly colocalized with the positivity to the
antibody against human HLA-A, B, and C confirming the
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Figure 1: LAM/TSC cells invade mouse lymph nodes and lungs causing lung nodules. (a) LAM/TSC cells are detected by immunoreactivity
to HLA-A, B, and C antibody (green labelling, arrows) in lymph nodes and PKH-26 fluorescence (red labelling) in nude mice 15 (𝑛 = 10),
30 (𝑛 = 13), and 60 (𝑛 = 12) weeks after cell administration (DAPI: blue labelling). (b) Staining with hematoxylin and eosin shows nodules
in mouse lungs 30 and 60 weeks after LAM/TSC cell administration. 15 weeks after cell administration, no nodules are observed. Scale bars:
200 𝜇m. Higher magnification scale bars: 100 𝜇m. (c) Percentage of mice with lung lesions 30 and 60 weeks after cell administration. Data are
expressed as mean ± SEM. (d) Lung nodules frommice of 30 weeks after cell administration are stained with 𝛼-actin (green) and anti-human
HLA-A, B, and C (orange) antibody. Colocalization of the markers appears yellow (arrows). Sections are stained with DAPI to show nuclei
(blue). Scale bars: 20 𝜇m. (e) EGFR is detected by immunoreactivity to EGFR antibody in lung nodules (green labelling) of nude mice 30
weeks after cell administration (DAPI: blue labelling). Scale bars: 20𝜇m.
presence of human LAM/TSC cells in nodules (Figure 1(d)).
EGFR was expressed in lung nodules (Figure 1(e)). Lung
morphology showed widespread tumor localization with cell
clusters of different size adjacent to bronchioles and to the
vessels. Some of the areas of lungs were, however, comparable
to the normal control indicating a considerable heterogeneity.
The mean tumor size was increased in a time-dependent
manner with a dimension of about 10337.228 ± 1.5 𝜇m and
14309.111±1.9 𝜇m30 and 60 weeks after cell administration,
respectively.
3.2. Anti-EGFR Antibody and Rapamycin Reduce the Num-
ber of Mice with Lung Lesions. Proliferation and survival
of LAM/TSC cells are EGF-dependent, as we previously
reported for 𝑇𝑆𝐶2−/− and 𝑇𝑆𝐶2−/meth cells, and anti-EGFR
antibody causes progressive cell death [14, 15, 21]. To assess
the in vivo action of anti-EGFR antibody on the lung
lesions caused by LAM/TSC cell administration, anti-EGFR
antibody were i.p. administered 26 weeks after cell inhalation
twice weekly for 4 weeks and then the mice were sacrificed.
Another group of mice were treated with rapamycin aiming
at testing and comparing the action of the inhibition of
mTOR with that of anti-EGFR antibody on the nodules. The
number of mice with lung nodules was significantly reduced
by anti-EGFR antibody treatment (about 33%) compared to
control (77%) whereas rapamycin was less effective (50%)
(Figure 2(a)). Moreover, the average area of the nodules
was also significantly reduced by treatment with anti-EGFR
antibody and rapamycin (Table 1).
The phosphorylation of S6, the downstream substrate
of mTOR and biomarker of cell lacking tuberin, and the
activation of extracellular-signal-regulated kinase (Erk), a
kinase of Ras/MAPK pathway, were studied to further eval-
uate the action of anti-EGFR antibody in lung nodules. The
phosphorylated form of both ribosomal proteins S6 and Erk
was broadly expressed in mice lung lesions (Figure 2(b)).
Anti-EGFR antibody reduced phospho-S6-positive cells in
pulmonary nodules in a comparable manner to that of
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Figure 2: Anti-EGFR antibody (Ab) reduces lung nodules caused by LAM/TSC cell administration and phosphorylation of S6 and Erk. (a)
Anti-EGFR Ab (𝑛 = 13) reduces the percentage of mice with lung nodules 30 weeks after cell administration more efficiently than rapamycin
(𝑛 = 11). Data are means ± SEM. #𝑃 < 0.05; ##𝑃 < 0.01 versus mice 30 weeks after cell administration (𝑛 = 13). (b) Immunohistochemical
analysis with phosphorylated S6 antibody at Ser235/236 (red staining, arrows) and phospho-Erk antibody atThr202/Tyr204 (brown staining)
in lung nodules 30 weeks after cell administration and after anti-EGFR antibody and rapamycin treatment. Scale bars: 10𝜇m. (c) The
expressions of EGFR (green labelling) and P-Erk (red labelling, upper panels) or P-S6 (red labelling, lower panels) are detected in LAM/TSC
cells, 24 hours after anti-EGFR Ab or rapamycin incubation. Scale bars: 50 𝜇m. (d) Western blotting analysis shows the decreased levels of
P-S6 and P-Erk following anti-EGFR Ab and rapamycin for 24-hour incubation in LAM/TSC cells. 𝛽-Actin is used as loading control.
Table 1: Nodule sizes were measured in mice lungs 30 weeks after cell administration (LAM/TSC cells) and following anti-EGFR antibody
or rapamycin treatment.
LAM/TSC cells Anti-EGFR antibody Rapamycin
Average are of nodule size (𝜇m2) 10.337,228 ± 1.469 6.291,569 ± 807,1∗ 4.822,547 ± 743,4∗
Data are expressed as mean ± SEM. ∗𝑃 < 0.05 versus mice 30 weeks after cell administration.
rapamycin (Figure 2(b)). However, the inhibition of Erk
phosphorylation in lung lesions was much higher with anti-
EGFR antibody rather than with rapamycin (Figure 2(b)). To
improve our understanding of these events we have evaluated
the activation of S6 and Erk by incubating LAM/TSC cells
with anti-EGFR antibody and rapamycin for 24 hours. Both
treatments slightly inhibited EGFR expression; anti-EGFR
antibodymarkedly reduced Erk and S6 phosphorylation and,
differently, rapamycin had a strong effect on phospho-S6 and
a slight one on phospho-Erk (Figures 2(c) and 2(d)).
3.3. Anti-EGFR Antibody Inhibits Estrogen and Progesterone
Receptor Expression and Snail. Estrogen promotes the pul-
monary metastasis of Tsc2-null ELT3 cells and the survival
of disseminated LAM cells facilitating lung colonization and
metastasis [7]. In lung lesions caused by administration of
LAM/TSC cells, the estrogen and progesterone receptors
were highly expressed (Figure 3(a)). Anti-EGFR antibody
reduced the expression of estrogen and progesterone recep-
tors such as rapamycin (Figure 3(a)). It has been recently
shown that the inhibition of ER in metastatic ovarian cancer
cells significantly reduces epithelial to mesenchymal transi-
tion (EMT) [22]. Snail, which takes place with the acquisition
of invasive properties in tumors, was highly expressed in
lung nodules and strongly reduced by the treatments with
anti-EGFR antibody and rapamycin (Figure 3(b)). However,
its pattern of expression was found to be heterogeneous
suggesting different states of EMT in all the groups. The
incubation of LAM/TSC cells with anti-EGFR antibody and
rapamycin for 24 hours inhibited the expression of Snail
confirming the data observed in lung nodules (Figure 3(c)).
3.4. Anti-EGFR Antibody Reverses Lung Degeneration Caused
by LAM/TSC Cell Administration. LAM is characterized
by abnormal proliferation of smooth muscle cells leading
to destruction of the lung architecture and formation of
pulmonary cysts. After administration of LAM/TSC cells,
histopathological changes with enlargement of the airspaces
and alveolar degeneration were observed (Figure 4(a)). The
alterationswere dependent on the time of cell administration,
significant morphological changes took place 15 weeks after
cell administration, and a more severe disruption of the
alveolar walls occurred after 30 and 60weeks. It is remarkable
that airspace enlargement preceded the formation of nodules,
which 15 weeks after cell administration were not observed.
Quantitative evaluation of the density of air-exchanging
parenchyma [𝐴
𝐴
(ae/lu)] confirmed the progressive and
time-dependent worsening of the lung architecture caused by
LAM/TSC invasion (Figure 4(b)).
The enlargement of alveolar spaces caused by LAM/TSC
cell administration was reversed after 4 weeks of treat-
ment with anti-EGFR antibody at 30 weeks following cell
administration (Figure 4(c)). In a similar way, rapamycin
reduced the alveolar enlargement but caused thickening of
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Figure 3:The anti-EGFR Ab treatment and rapamycin reduce the expression of estrogen and progesterone receptors and Snail in pulmonary
nodules. (a) Immunohistochemical analysis of lung nodules 30 weeks after cell administration shows a very high expression of estrogen
and progesterone receptors (brown staining) which is decreased by anti-EGFR Ab and rapamycin. Scale bars: 10 𝜇m. (b) Expression of Snail
(brown staining) is inhibited by the two drugs in lung nodules. Scale bars: 50 𝜇m. (c) Anti-EGFR Ab and rapamycin incubation for 24 hours
reduce Snail level in LAM/TSC cells. 𝛽-Actin is evaluated as loading control. COS7 cells are used as control.
lung parenchyma (Figure 4(c)). Quantitative evaluation of
the density of air-exchanging parenchyma confirmed the
efficacious action of the treatments and the thickening action
of rapamycin on lung parenchyma (Figure 4(d)).These sets of
data confirm our previous data showing that rapamycin and,
more efficiently, anti-EGFR antibody reverse the structural
lung alterations caused by 𝑇𝑆𝐶2−/− ASM cell administration
in nude mice [20].
3.5. Anti-EGFRAntibody Reduces Angiogenesis and Lymphan-
giogenesis Caused by LAM/TSC Cell Administration. Numer-
ous blood vessels were observed in mice lungs after 6 month
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Figure 4: LAM/TSC cell administration causes enlargement of the airspaces that reverted by anti-EGFR Ab and rapamycin treatment. (a)
LAM/TSC cells cause progressive lung degeneration. Lungs of nude mice 15, 30, and 60 weeks after LAM/TSC cell administration (lower
panels) are stained with hematoxylin and eosin and compared to control of the same age (upper panels). Scale bars: 200 𝜇m. (b) The 𝐴
𝐴
(ae/lu) (fraction of air exchanging parenchyma relative to lung parenchyma) is shown as themean of±SEMof 10 animals per group, expressed
as a percentage. ∗∗∗𝑃 < 0.001 versus 𝐴
𝐴
(ae/lu) in control; ##𝑃 < 0.01 versus 𝐴
𝐴
(ae/lu) in mouse lungs 15 weeks after LAM/TSC cell
administration; †𝑃 < 0.05 versus 𝐴
𝐴
(ae/lu) in mouse lungs 30 weeks after LAM/TSC cells administration. (c) Anti-EGFR Ab reduces the
enlargement of airspaces caused by LAM/TSC cell administration such as rapamycin that induced a thickening of the parenchyma. Scale bars:
200 𝜇m. (d)The𝐴
𝐴
(ae/lu) relative to controlmice, 30-week LAM/TSC cell-administeredmice,mice treatedwith anti-EGFRAbor rapamycin
is shown as the mean of ±SEM of 10 animals per group, expressed as percentage. ∗∗𝑃 < 0.01, 𝐴
𝐴
(ae/lu) in lungs of cell-administered mice
versus 𝐴
𝐴
(ae/lu) in lungs of control mice. ###𝑃 < 0.001 𝐴
𝐴
(ae/lu) in lungs of drug-treated mice after cell administration versus lungs of
cell-administered mice.
from LAM/TSC cell administration indicating a specific
ability of these cells to cause angiogenesis (Figure 5(a)). Anti-
EGFR antibody and rapamycin reduced the number of blood
vessels as demonstrated quantitatively by counting blood
vessels/fields (Figures 5(a) and 5(b)).
Lymphatic involvement in human LAMhas been demon-
strated by abundant lymphatics in human LAM lungs and
LAM lesions [23]. Lymphatic vessel density (LVD) based on
LYVE 1 staining, well-known lymphatic capillary marker and
lymph-specific receptor for hyaluronan, was much higher
in lung parenchyma 30 weeks after LAM/TSC cell admin-
istration than in controls and was markedly present in lung
nodules (Figures 5(c) and 5(d)). These findings indicate that
LAM/TSC cells, once in the lungs, promoted the proliferation
of LYVE 1-positive lymphatic vessels. Both anti-EGFR anti-
body and rapamycin treatments counteracted the increase of
LYVE 1 expression and LVD (Figures 5(c) and 5(d)).
4. Discussion
EGFR signaling can lead to a variety of downstream effects
controlled by complex regulatory mechanisms. The activa-
tion of the EGFR causes the recruitment and phosphoryla-
tion of several intracellular substrates, leading to mitogenic
signaling and other cellular activities [1]. These events are
mediated by a complex series of signaling mechanisms,
such as engagement of the mitogen-activated protein kinase
(MAPK) and Stat and phosphatidylinositol-3 kinase (PI3 K)
pathways [24]. Although expressed in nonmalignant cells,
the EGFR is highly expressed in a variety of tumors leading
to its validation as a therapeutic target in several human
tumors, including colorectal cancer, breast cancer, and head
and neck cancer [25, 26]. We previously demonstrated that
tuberin-null cells, isolated either from angiomyolipoma or
chylothorax of TSC and LAM patients, depend on EGF for
survival and proliferation and this dependency is related to
tuberin absence [14–16]. Moreover, enhanced expression of
EGF and EGFR has been demonstrated in mouse cortex
of 𝑇𝑠𝑐1GFAP CKO and in TSC tubers and SEGAs of TSC
patients suggesting that the altered growth factor expression
may be the consequence of loss of tuberin or hamartin
[19]. Very recently it has been described that absence of
tuberin leads to abundant nuclear localization of EGFR in
rat uterine leiomyoma-derived and LAM patient-derived
cells [27]. Given the recent evidences regarding EGF and
EGFR and the need to identify specific target for therapeutic
approach in LAM and TSC, our aim was to elucidate the
role of EGF and EGFR in the pathogenesis of these diseases.
For this purpose, we took advantage of a mouse model
developed by endonasal administration of LAM/TSC cells
in nude mice [28]. LAM/TSC cells metastasized and caused
lung damage with enlargement of the alveolar walls and
nodule formationwith a time-dependentworsening.Wehave
previously developed a similar mouse model by endonasal
administration of 𝑇𝑆𝐶2−/− ASM cells that shows enlarged
airspaces but not lung nodules leading to speculating that
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Figure 5: 30 weeks after administration LAM/TSC cells cause an increase of blood and lymphatic vessels which is counteracted by anti-EGFR
Ab. (a) Representative images of lungs stained with hematoxylin and eosin are shown. Scale bars: 200𝜇m. (b) Quantification of blood vessels
is done by counting the number of vessels in a field (6 fields for 8 mice for each group). Data are expressed as mean ± SEM. ∗∗∗𝑃 < 0.001
versus control mice. ##𝑃 < 0.01 versus LAM/TSC-administeredmice. (c) Lymphatic capillary marker LYVE-1 (green labelling) is expressed in
lung nodules and is inhibited by anti-EGFR Ab and rapamycin. Sections are stained with DAPI to show nuclei (blue). Representative images
are shown. Scale bars: 75 𝜇m. (d) LVD is calculated in five fields of lung parenchyma for each mouse. Data are expressed as mean ± SEM.
∗∗∗
𝑃 < 0.001 versus LVD of control mice. ##𝑃 < 0.01 versus LVD of LAM/TSC-administered mice.
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these latter lesions might be caused by the intrinsic cellular
characteristics of LAM/TSC cells, such as their mesenchymal
features, and to cell administration during the development
from infancy to adulthood, which better resembles the
natural hormonal development occurring in patients [20].
LAM/TSC cells were present in lung nodules and, similarly
to a variety of human tumors and EGFR was also expressed
supporting its important role in the development of lung
alterations and as possible therapeutic target. For the EGFR
expression in lung nodules and the specific cytotoxic effect
of anti-EGFR antibody in LAM/TSC cells, we studied anti-
EGFR action on the lung lesions comparing the results with
rapamycin effect. For the constitutive activation of mTOR
signaling pathway, mTOR inhibition with rapamycin analogs
has been considered as the primary target for therapies
for TSC and LAM [12, 29]. Rapamycin causes a cytostatic
response in TSC cells and in TSC-associated tumors and
stabilized lung function and improved symptoms of LAM
patients. However, upon rapamycin withdrawal, most disease
symptoms reappear, and hamartomas and lung function
declined supporting the need to identify alternative targets
for therapies. Rapamycin and anti-EGFR antibody decreased
the size of pulmonary nodules. Anti-EGFR antibody signif-
icantly reduced the percentage of mice with lung nodules
more efficiently than rapamycin likely by inhibiting activation
of Erk as well as S6 phosphorylation as demonstrated in
vitro in LAM/TSC cells. These sets of data suggest that the
modulation of Erk through EGFR together with S6 activation
controls TSC and LAM cell survival and proliferation. The
role of Erk in LAM has been suggested in recent reports
showing that, by modulation of MEK pathway, estrogen
promotes the invasion of cells derived from Eker rat uterine
leiomyoma in the lungs of ovariectomized mice [7]. LAM
lesions generally express estrogen and progesterone receptors
suggesting a role for reproductive hormones in the devel-
opment of the disease [7]. Estrogen enhances the neoplastic
potential and survival of LAM cells [4]. In lung lesions of
LAM/TSC cell-administrated nude mice, the estrogen and
progesterone receptors were highly expressed. Inhibition of
EGFR signaling with anti-EGFR antibody or mTOR with
rapamycin strongly reduced these receptors levels.
LAM has been classified and clinically managed as a non-
neoplastic interstitial lung disease but, recently, the reclas-
sification of LAM as a low-grade, destructive, metastasizing
neoplasm has been proposed [30]. EMT is considered a key
step in metastasis in which epithelial cancer cells acquire
mesenchymal features such as motility and invasiveness [31].
The interaction of estrogen-Erk pathway and hyperactivated
mTOR controls Fra1 translation of Fra1 mRNA to promote
migration and invasion in LAM cells [32]. Moreover, Erk2
isoform overexpression induces Ras-induced EMT in MCF-
10A cells with a change in morphology and reduced E-
cadherin levels [33]. In lung nodules of our mouse model,
Snail, a repressor of E-cadherin and an inducer of EMT, was
highly expressed such as that in LAM/TSC cells. Anti-EGFR
antibody and rapamycin inhibited the expression of Snail in
lung nodules and in LAM/TSC cells. These sets of data are in
line with the evidences that EGFR activation promotes EMT
and contributes to the acquisition of an invasive phenotype
and, consequently, the inhibition of EGFR blocks cell motility
and EMT marker expression [34, 35]. EMT features in lung
nodules and LAM/TSC cells are also inhibited by rapamycin.
Recent reports have suggested a role for mTOR in the EMT
events, but with conflicting results. In colorectal cancer
cells and in murine mammary epithelial NMuMG cells,
the inhibition of mTOR signaling reduces migration and
invasion [36, 37]. However, other authors demonstrated a
pro-EMT effect of rapamycin with an increased invasive
phenotype in epithelial cell lines [38, 39]. In tuberin-null cell,
the lack of tuberin induces EMT features with high levels
of Snail and reduced cell-cell adhesion demonstrating an
invasive growth pattern in human TSC pathological lesions
[15, 40]. Accordingly, in LAM/TSC cells and in lung nodules
rapamycin reduces EMT features through the inhibition of
mTOR.
Lymphatic vessels as routes for trafficking through the
body are used not only by immune cells but also by cancer
cells. Metastasis to regional lymph nodes represents the
first step of tumor dissemination in many cancer cells and
is an important prognostic indicator for disease progres-
sion. A number of studies have established that tumors
can actively induce tumor-associated lymphangiogenesis
by secreting appropriate growth factors such as vascular
endothelial growth factor- (VEGF-) C, VEGF-D, or VEGF-A
and EGF [41, 42]. EGFR activation has been shown to
enhance processes responsible for tumor growth and pro-
gression, including the promotion of proliferation, invasion/
metastasis, inhibition of apoptosis, and neoangiogenesis [43].
It has been reported that tuberin-null cells promote lymphatic
growth and migrate through lymphatic vessels [20, 44, 45].
Following LAM/TSC administration, LYVE-1 labeling was
significantly increased and was mainly localized near and
in lung nodules. In uterus of this mouse model, lymphatic
growth and morphological alterations were not observed
suggesting a specific recruitment of LAM/TSC cells and
developing abnormal processes in lung [28]. Differently from
the previous model developed by using TSC2−/− cells, 30
weeks after LAM/TSC cell administration inmouse lungs, the
number of blood vessels was significantly increased such as
that in uteri, suggesting that the promotion of blood vessels
formation might be caused by LAM/TSC cell infiltration in
lung in a similar way to what was observed in uterus [28].
5. Conclusions
In conclusion, LAM/TSC cell administration in nude mice
caused pulmonary alterations, in particular alveolar enlarge-
ment and lung nodules that express EGFR and, as LAM/TSC
cells, are responsive to the blockade of EGFR. Anti-EGFR
antibody reduced the number of lung nodules more effec-
tively than rapamycin likely for the combined inhibition of
Erk activity and S6 phosphorylation. Anti-EGFR antibody
inhibited EMT and expression of progesterone and estrogen
receptors, typical features of TSC lesions and LAM cells. Our
data reinforce the importance to consider EGFR as a target
in LAM and TSC cells and to test the potential therapeutic
function of anti-EGFR. Moreover, also in combination with
rapamycin, anti-EGFR antibody might be a good candidate
BioMed Research International 13
to control the altered pathways in LAM and TSC cells such as
cell growth, proliferation, migration/invasion, and survival.
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